Dr Charlotte Pawlyn speaks to ecancer at ASH 2018 about the results of the Myeloma XI study.
The work being presented was focused on results from the comparison between a quadruplet regimen comprising of carfilzomib, cyclophosphamide, lenalidomide, and dexamethasone (KCRD) vs an immunomodulatory agent containing triplet (CTD/CRD) induction therapy for transplant eligible patients.
Dr Pawlyn explains that the results showed that the quadruplet led to deeper responses and prolonged progression free survival.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.